Fate Therapeutics Inc
FATEFate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California. Address: 12278 Scripps Summit Drive, San Diego, CA, United States, 92131
Analytics
主に工業および宝飾用の金属です。市場が不況を予想し、生産が低下すると、価値は下がります。宝飾品業界からの需要も不安定です。現在、プラチナは金よりも安く、それで作られたアイテムはエリートと見なされません。
6.31 USD生産が消費をまかなえない場合、供給不足の脅威があります。物理的な金属の不足への恐れの中で、価格は上昇します。しかし、これが不況の予想とともに起こると、価格にはほとんど影響がありません。これは2008年と2023年に明確に見られました。
–配当利回り
–今年
去年
今四半期
前四半期
今年
去年
今四半期
前四半期
主要人物 FATE
配当分析 FATE
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–